Effect of tablet Melatonin on prevention of Confusion in severe COVID 19 patients admitted in ICU

Effect of Melatonin on prevention of delirium in severe COVID-19 patients admitted in ICU. A double blind randomised control trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/12/038630

Enrollment

140

Registered

2021-12-15

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: U071- COVID 19 virus identified

Interventions

Intervention1: Melatonin 3 and 6 mg in icu admitted COVID-19 patients: Melatonin 3 mg to one group and 6 mg to other group in severe COVID-19 patients at 6pm every day till the patient is in icu Contr

Eligibility

Inclusion criteria

Inclusion criteria: RTPCR / CT proven COVID-19 pneumonia with saturation less than 93%.

Exclusion criteria

Exclusion criteria: Post cardiac arrest Patients on opioid antagonist, chronic opioid or sleeping pills, SSRI, Monoamine oxidase inhibitors, central nervous system depressants Patients with cerebrovascular accident and other CNS disorders.

Design outcomes

Primary

Measure	Time frame
To study the effect of melatonin on incidence of onset of delirium on day 3 of delirium Timepoint: Day 3rd of icu	—

Secondary

Measure	Time frame
To study the effect of melatonin on mortality, icu stay, duration of ventilator supportTimepoint: Number of day in icu and on duration of ventilator support in days	—

Countries

India

Contacts

Public ContactDr Vijay Kumar

Bangalore medical college and research institute

vijay.bmc.ccm@gmail.com9886504680

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026